FDA-approved ROS scavenger for ALS and stroke, useful reference compound but not frontier research
Look, edaravone has a genuinely interesting story on paper: a pyrazolone compound that scavenges peroxyl and hydroxyl radicals, approved in Japan for acute ischemic stroke back in 2001 and then FDA-approved for ALS in 2017 under Radicava. Thats a real clinical track record. The oral formulation (Radicava ORS) added in 2022 improved the accessibility picture considerably. So why aren’t we more excited about it?
The mechanism is the issue. Free radical scavenging as a primary MoA is one of those ideas that looks elegant until you zoom out and count how many antioxidant compounds have failed to translate in neurodegeneration trials. Oxidative stress is absolutely real in ALS pathology, and edaravone’s Japanese phase 3 (MCI186-19) did show slowed functional decline on the ALSFRS-R. But that trial enrolled a carefully selected subset: early disease, preserved respiratory function, no comorbidities that would confound. Whether the signal holds in broader populations is genuinely contested. The Japanese and US regulatory bodies accepted it; a meaningful portion of neurologists remain unconvinced of real efficacy in typical ALS patients.
As a research tool, edaravone’s strongest role is probably as the canonical ROS scavenger reference compound in neurology and ischemic injury models. If you’re running oxidative stress assays in neural cell lines or rodent stroke preparations, it’s a clean, well-characterized probe with predictable pharmacokinetics (plasma half-life around 4.5 hours). That utility is real. It’s not going to answer questions that N-acetylcysteine or MnTBAP couldn’t also probe, but the regulatory-grade characterization makes it a credible positive control in publication-facing work.
What we like: the ALS approval gives investigators a legitimate clinical hook, and edaravone is one of only two approved pharmacological options for the disease (alongside riluzole), which means it gets used in the field whether researchers are excited by the mechanism or not. The transition to oral dosing also solves some practical barriers for repeat-exposure study designs.
What we don’t like: free radical scavenging is not a frontier mechanism. That’s been the central critique of the entire antioxidant therapeutic category for decades. The subset-specificity of the phase 3 data makes translational extrapolation genuinely uncertain, and the compound itself doesn’t open any research question that other tools can’t address. Honestly, edaravone sits in the ‘approved tool with modest novelty’ bucket. Researchers in ALS biology will have it in their toolkit by necessity; investigators outside that specific indication don’t have strong reason to prioritize it over more targeted probes.